JP2022526017A5 - - Google Patents

Info

Publication number
JP2022526017A5
JP2022526017A5 JP2021559826A JP2021559826A JP2022526017A5 JP 2022526017 A5 JP2022526017 A5 JP 2022526017A5 JP 2021559826 A JP2021559826 A JP 2021559826A JP 2021559826 A JP2021559826 A JP 2021559826A JP 2022526017 A5 JP2022526017 A5 JP 2022526017A5
Authority
JP
Japan
Prior art keywords
compound according
appears
independently
following structure
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559826A
Other languages
English (en)
Japanese (ja)
Other versions
JP7618137B2 (ja
JP2022526017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027755 external-priority patent/WO2020210692A1/en
Publication of JP2022526017A publication Critical patent/JP2022526017A/ja
Publication of JP2022526017A5 publication Critical patent/JP2022526017A5/ja
Priority to JP2025002846A priority Critical patent/JP2025065129A/ja
Application granted granted Critical
Publication of JP7618137B2 publication Critical patent/JP7618137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559826A 2019-04-11 2020-04-10 プログラム可能なポリマー薬 Active JP7618137B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002846A JP2025065129A (ja) 2019-04-11 2025-01-08 プログラム可能なポリマー薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962832726P 2019-04-11 2019-04-11
US62/832,726 2019-04-11
US201962877151P 2019-07-22 2019-07-22
US62/877,151 2019-07-22
PCT/US2020/027755 WO2020210692A1 (en) 2019-04-11 2020-04-10 Programmable polymeric drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002846A Division JP2025065129A (ja) 2019-04-11 2025-01-08 プログラム可能なポリマー薬

Publications (3)

Publication Number Publication Date
JP2022526017A JP2022526017A (ja) 2022-05-20
JP2022526017A5 true JP2022526017A5 (enExample) 2023-04-18
JP7618137B2 JP7618137B2 (ja) 2025-01-21

Family

ID=70482850

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559826A Active JP7618137B2 (ja) 2019-04-11 2020-04-10 プログラム可能なポリマー薬
JP2025002846A Pending JP2025065129A (ja) 2019-04-11 2025-01-08 プログラム可能なポリマー薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002846A Pending JP2025065129A (ja) 2019-04-11 2025-01-08 プログラム可能なポリマー薬

Country Status (6)

Country Link
US (1) US20220168433A1 (enExample)
EP (1) EP3952917A1 (enExample)
JP (2) JP7618137B2 (enExample)
KR (1) KR20210152524A (enExample)
CN (1) CN113905766A (enExample)
WO (1) WO2020210692A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
WO2016138461A1 (en) 2015-02-26 2016-09-01 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
KR102646956B1 (ko) 2015-02-26 2024-03-14 소니그룹주식회사 페닐에티닐나프탈렌 염료 및 이의 사용 방법
KR102765335B1 (ko) 2015-05-11 2025-02-13 소니그룹주식회사 초휘도 이량체성 또는 중합체성 염료
BR112018070164B1 (pt) 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
EP3436528B1 (en) 2016-04-01 2025-07-02 Sony Group Corporation Ultra bright dimeric or polymeric dyes with rigid spacing groups
CN109153860B (zh) 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
BR112018073199A2 (pt) 2016-05-11 2019-04-16 Sony Corporation corantes diméricos ou poliméricos ultrabrilhantes
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
WO2019140128A1 (en) 2018-01-12 2019-07-18 Sony Corporation Phosphoalkyl polymers comprising biologically active compounds
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3769085B1 (en) 2018-03-19 2022-08-24 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
CN113905766A (zh) * 2019-04-11 2022-01-07 索尼集团公司 可编程的聚合药物
EP3861074A2 (en) 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9545447B2 (en) * 2013-01-04 2017-01-17 The Texas A&M University System Polymer-drug systems
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
WO2016138461A1 (en) 2015-02-26 2016-09-01 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
KR102765335B1 (ko) * 2015-05-11 2025-02-13 소니그룹주식회사 초휘도 이량체성 또는 중합체성 염료
BR112018073199A2 (pt) * 2016-05-11 2019-04-16 Sony Corporation corantes diméricos ou poliméricos ultrabrilhantes
KR20260011205A (ko) * 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN113905766A (zh) * 2019-04-11 2022-01-07 索尼集团公司 可编程的聚合药物

Similar Documents

Publication Publication Date Title
JP2022526651A5 (enExample)
JP2022526014A5 (enExample)
JP7703727B2 (ja) 抗her2抗体-薬物コンジュゲート
WO2020210689A1 (en) Programmable polymeric drugs
EP3952917A1 (en) Programmable polymeric drugs
WO2020210694A1 (en) Programmable polymeric drugs
AU2007315211B2 (en) FGFR4 antibodies
JP2023551355A (ja) 抗腫瘍化合物並びにその調製方法及び使用
KR102941769B1 (ko) 항her3 항체-약물 콘주게이트
CN102892787B (zh) 放射性金属标记抗钙粘素抗体
CA2467738A1 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
JP2017158569A (ja) ヘテロ多量体分子を作製するための方法
JP2024537069A5 (enExample)
US20250009786A1 (en) Automated synthesis of polymeric dual drugs
JP2024536224A5 (enExample)
JP2025514636A5 (enExample)
WO2023052970A1 (en) Pyrrolobenzodiazepine conjugates for cancer treatment
JP2024508886A (ja) 抗体-オリゴヌクレオチドコンジュゲートを使用した標的化の増強
KR20230142530A (ko) 항체-약물 접합체 및 이의 의학적 용도
CN118139891A (zh) 抗体药物偶联物及其制备方法和医药用途
TW202517255A (zh) 化合物、組合物及方法
WO2026057076A1 (zh) 基于抗liv-1抗体-药物偶联物的耐药癌症的治疗
TW202504641A (zh) 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
CN118159296A (zh) 聚合型双药的自动合成
CN119818701A (zh) 抗体药物偶联物及其医药用途